VITAPROSTAT
UkraineThe drug is used to treat chronic prostatitis, prostate adenoma, age-related functional disorders, and urinary disorders, as well as complications following prostate surgery, male infertility, and copulatory dysfunction.
Frequently asked questions
How should Vitaprostat be taken correctly?
The drug is administered intramuscularly once daily at a dose of 1-2 vials per day. Before administration, the powder from the vial must be dissolved in 1-2 ml of water for injection, saline, or novocaine. The course of treatment usually lasts from 5 to 10 days; if necessary, it can be repeated after 1-6 months.
What side effects can Vitaprostat cause?
Possible allergic reactions include itching or rash, as well as changes at the injection site.
Who should not use this drug?
The drug is not prescribed for women and children. It is also contraindicated in individuals with hypersensitivity to its components or to bovine proteins.
Can the drug be mixed with other medicines?
The drug should not be mixed with other medicinal products in the same syringe. Use only the recommended solvents.
Does the drug affect interactions with other medicines?
Interactions with other medicinal products have not been studied at this time.
Instructions for use
INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT VITAPROST (VITAPROST)
Composition:
Active substance: 1 vial contains lyophilized from aqueous solution of extract of bull prostate gland obtained by extraction, equivalent to not less than 2.0 mg of polypeptides
Excipient: glycine
Pharmaceutical form. Lyophilisate for solution for injection.
Main physicochemical properties: amorphous powder or porous mass of white or white with yellowish tint color.
Pharmacotherapeutic group. Agents used in benign prostatic hyperplasia. ATC code G04CX.
Pharmacological Properties.
Pharmacodynamics.
Vitaprost exerts a specific organotropic effect on the prostate gland. In prostate diseases, the drug, as a pathogenetically acting agent, normalizes microcirculation processes and platelet-vascular hemostasis, reduces or eliminates tissue edema and leukocyte infiltration (including decreasing leukocyte content in glandular secretions), exerts an indirect bacteriostatic effect on the microflora of the secretion, reduces the titer of detected pathogens to complete sterility or suppresses microbial viability. Vitaprost normalizes spermatogenesis (increases the number and motility of spermatozoa), demonstrates a modulating effect on T- and B-lymphocyte status, regulates the tone of urinary bladder muscles, including detrusor tone, and enhances the body's nonspecific resistance.
Pharmacokinetics.
The peptide drug Vitaprost is degraded by cellular proteases into amino acids. Vitaprost and its metabolites are excreted in urine. The drug does not exhibit a cumulative effect.
Clinical characteristics.
Indications.
Chronic prostatitis, benign prostatic hyperplasia, age-related disturbances of its functions and associated disorders of urination, postoperative complications following prostate surgery; interoceptive copulative dysfunction; male infertility.
Contraindications. Hypersensitivity to the components of the drug or to bovine proteins.
Interaction with other medicinal products and other forms of interaction. Not studied.
Special precautions. During treatment with the drug, it is recommended to monitor clinical markers of prostate gland activity (prostate-specific antigen).
Use during pregnancy or breastfeeding. The drug is not administered to women.
Ability to influence reaction rate while driving or operating machinery. Not studied.
Method of Administration and Dosage.
To be used for the treatment of adults, including elderly men. Administer intramuscularly. Before use, dissolve the contents of the vial in 1–2 mL of water for injections, 0.9 % sodium chloride solution, or 0.5 % procaine solution. If procaine is used as the solvent, the safety information regarding procaine must be taken into account. The drug should be administered daily, 1–2 vials once a day. The treatment course lasts 5–10 days. If necessary, repeat the course (after 1–6 months).
Children. The drug is not used in children.
Overdose. Not studied.
Side effects.
Allergic reactions are possible, including itching, rash; changes at the injection site.
Shelf life. 3 years.
Storage conditions. Store in the original packaging to protect from light at a temperature not exceeding 25°C.
Incompatibility. The drug should not be mixed with other medicinal products in the same syringe. Use only recommended solvents.
Packaging. 5 vials with lyophilisate in a blister, 2 blisters per carton.
.
Prescription category. By prescription only.
Manufacturer. LLC "FZ "STADA", Ukraine.
Manufacturer's location and address of the place of business activity.
Ukraine, 09100, Bila Tserkva, Kyivska St., 37, Kyiv region.
The original data is available in the language of the country of manufacture.
Data source: State Register of Medicinal Products of Ukraine
Data last verified: August 13, 2026